BACK
IMAC Holdings Inc
Q1 2025 Report
IMAC Holdings Inc (BACK) Q1 2025 Results - A Challenging Quarter with Strategic Focus on Recovery...
Read full report
Executive Summary
In Q3 2024, IMAC Holdings Inc (NASDAQ: BACK) reported significant financial challenges, reflecting ongoing pressures in the healthcare sector, specifically within regenerative medicine. The company experienced total revenues of $56,300, showcasing a sharp decrease of 96.40% year-over-year. This decline highlights the robust competition and operational inefficiencies faced by IMAC as it continues its efforts toward recovery. With a loss of $2,204,648 in net income and a negative EPS of $1.56, the financials signal pressing headwinds that are alarming for investors, despite increases in cash flow activities from reducing operational expenses and restructuring efforts.
The company attributed these results to elevated labor costs and reduced patient volumes that have greatly affected profitability. Management remains focused on strategic initiatives to enhance operational efficiency and expand service offerings, reaffirming their commitment to long-term recovery and growth in the face of adversity.
Key Performance Indicators
Revenue
56.30K
QoQ: 257.46% | YoY:-96.40%
Gross Profit
-65.78K
-1.17% margin
QoQ: -16.93% | YoY:-110.06%
Operating Income
-2.00M
QoQ: -42.38% | YoY:31.11%
Net Income
-2.20M
QoQ: -59.36% | YoY:24.31%
EPS
-1.56
QoQ: -33.33% | YoY:40.68%
Revenue Trend
Margin Analysis
Key Insights
**Revenue Performance:** IMAC's revenue for Q3 2024 stood at $56,300, marking a 257.46% rise from Q2 2024 but a staggering 96.40% decline year-over-year. It's critical to note that this recovery from the previous quarter can be misleading without sustained customer engagement. **Profitability:** The gross profit margin fell drastically to -1.17, indicating an unsustainable cost structure. Operating income showed slight improvement, deteriorating at a lower rate (-35.45% operating inc...